NICE has just published draft guidance recommending the use of ocriplasmin (Jetrea, ThromboGenics) as an option for the treatment of vitreomacular traction in adults, including when associated with a macular hole with a diameter of 400 micrometres or less, only if they have severe symptoms and an epiretinal membraneii is not present. Final guidance is expected in October 2013. For more details, go to http://www.nice.org.uk/newsroom/pressreleases/NICEYesEyeConditionTreatmentDraftGuidance.jsp

Meanwhile, IQWIG has announced this week that it has started its assessment of Jetrea following the awarding of a commission awarded on 30.04.2013 by the Federal Joint Committee (G-BA).  For more details, go tohttps://www.iqwig.de/en/projects_results/projects/drug_assessment/a13_20_ocriplasmin_benefit_assessm...